Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 43 clinical trials
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Talazoparib has shown clinical efficacy in breast cancer patients with germline BRCA1 or BRCA2 mutations. Beyond BRCA1 and BRCA2 mutations, it is plausible that talazoparib may have activity in

  • 0 views
  • 07 Oct, 2022
  • 1 location
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes

The purpose of this study is to evaluate how effective the study drugs, nivolumab (also known as Opdivo®) and talazoparib (also known as Talzenna®) are when given as a combination treatment for

  • 96 views
  • 14 Apr, 2022
  • 1 location
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

This research study is evaluating a drug called Avelumab alone and in combination with Talazoparib or Axitinib as a possible treatment for recurrent or metastatic endometrial cancer.

  • 165 views
  • 10 Jul, 2022
  • 4 locations
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer (CHANGEABLE)

obstacles of DNA damage repair(DDR), accumulation of DNA damage, thus promote the apoptosis of tumor cells. Several PARPi have been approved worldwide (including Olaparib, Rucaparib, Niraparib, Talazoparib

  • 0 views
  • 09 Jul, 2022
  • 1 location
TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR

  • 0 views
  • 25 Oct, 2022
  • 211 locations
Study of RP-3500 in Advanced Solid Tumors

combination with talazoparib, a PARP inhibitor, or Gemcitabine in patients with advanced solid tumors with ATR inhibitor-sensitizing mutations. This study will also evaluate the safety and tolerability of RP

  • 4 views
  • 07 Oct, 2022
  • 11 locations
BrUOG 390: Neoadjuvant Treatment With Talazoparib

Ovarian cancer is the most fatal gynecologic cancer; in the US alone an estimated 22,000 women will be diagnosed in 2019, with over 13,000 dying of the disease. Approximately half of epithelial ovarian cancers (EOC) exhibit defective DNA repair through alterations in the homologous recombination (HR) pathway, with 14% accounted …

colony stimulating factor
parp inhibitor
breast cancer
endometrioid adenocarcinoma
BRCA2
  • 0 views
  • 04 Oct, 2022
  • 2 locations
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

This trial is testing whether molecularly targeted oral medications called talazoparib and tazemetostat can be safely combined for the treatment of prostate cancer, and whether the combination

  • 0 views
  • 04 Oct, 2022
  • 2 locations
Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

In view of the strong biological rationale of employing PARP inhibition in high grade glioma, the current study purposes testing of talazoparib in a biomarker-enriched group of glioma

  • 0 views
  • 25 Aug, 2021
  • 1 location
Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

The purpose of this study is to see whether the combination of avelumab and talazoparib can be an effective treatment for metastatic renal cell carcinoma.

pd-l1
metastatic renal cell carcinoma
hysterectomy
programmed cell death 1 ligand 1
oophorectomy
  • 2 views
  • 23 Mar, 2022
  • 7 locations